Gapping up
In reaction to earnings/guidance:
- ALGN +26.9% (also introduces Invisalign G8 with new SmartForce Aligner Activation), OPTN +14%, BCOV +12.4%, SNA +9.5%, PTEN +9.2%, AXTA +7%, RUSHA +6.4%, WSO +5.5%, DFS +5.3%, TSLA +5%, LVS +5%, SLM +4.9%, UFPI +4.8%, CSX +4.7% (also authorizes $5 bln share buyback), PAG +4.4%, TPH +4.3%, WHR +4.2%, ENTG +4.1%, SLG +3.1%, VMI +3%, CHKP +2.8%, KO +2.7%, SIRI +2.6%, FTI +2.5%, UMPQ +2.5%, SEIC +2.4%, STM +2.3%, T +2.3%, DOW +2.2%, ALLE +2%, HRI +1.9%, CTXS +1.9%, DGX +1.8%, FITB +1.7%, VIAV +1.6% (also new CFO), DHR +1.5%, NOC +1.5%, PDS +1.4%, NTGR +1.3%, PHM +1.2%, WSBC +1%
Other news:
- ALLK +5.6% (publishes results from Phase 2 study of lirentelimab)
- MLCO +4.1% (in sympathy with LVS)
- NK +3.9% (doses the first patient in the Phase 1 clinical trial of hAd5-COVID-19)
- UXIN +3.7% (announces launch of prorietary used car rating system)
- YCBD +3% (announces expansion of cbdMD product sales into Life Time Cafes nationwide)
- WYNN +2.5% (in sympathy with LVS)
- BCRX +2.2% (publication of data from the APeX-2 trial of berotralstat in patients with hereditary angioedema)
- GILT +2.2% (awarded $20 mln cellular backhaul managed service contract renewal and expansion)
- OBSV +1.8% (presents two late-breaking posters at the ASRM 2020 Virtual Scientific Congress)
- CZR +1% (in sympathy with LVS)
Analyst comments:
- XRAY +3.1% (upgraded to Buy from Neutral at Guggenheim)
- IRBT +1.8% (upgraded to Outperform from Mkt Perform at Raymond James)
- H +0.8% (upgraded to Hold from Underperform at Gordon Haskett)
- ERIC +0.5% (upgraded to Buy from Hold at Danske Bank)